Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 193-201

  Levites, Yona ^a   Das, Pritam ^a   Price, Robert W ^a   Rochette, Marjorie J ^a   Kostura, Lisa A ^a   McGowan, Eileen M ^a   Murphy, Michael P ^a   Golde, Todd E ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-16] MONOCLONAL ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-40] MONOCLONAL ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; IN VIVO STUDY; INJECTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; PEPTIDE FRAGMENTS;

EID: 31044433933     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25410     Document Type: Article

References (50)

1. Das, P., et al. 2003. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 23:8532-8538.
2. Hardy, J., and Selkoe, D.J. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-356.
3. Iwatsubo, T., et al. 1994. Visualization of A beta 42(43) and A beta 40 in senile plaques with andspecific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 13:45-53.
4. Gravina, S.A., et al. 1995. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270:7013-7016.
5. Golde, T.E., Eckman, C.B., and Younkin, S.G. 2000. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:172-187.
6. Klein, W.L., Stine, W.B., Jr., and Teplow, D.B. 2004. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging. 25:569-580.
7. Walsh, D.M., and Selkoe, D.J. 2004. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11:213-228.
8. Younkin, S.G. 1998. The role of A beta 42 in Alzheimer's disease. J. Physiol. (Paris). 92:289-292.
9. Jarrett, J.T., Berger, E.P., and Lansburry, P.T., Jr. 1993. The carboxy terminus of β amyloid protein is critical for the seeding of amyloid formation: implications for pathogenesis of Alzheimer's disease. Biochemistry. 32:4693-4697.
10. Scheuner, D., et al. 1996. Secreted amyloid betaprotein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:864-870.
11. Duff, K., et al. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710-713.
12. Games, D., et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:523-527.
13. McGowan, E., et al. 2005. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 47:191-199.
14. Iijima, K., et al. 2004. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101:6623-6628.
15. Greeve, I., et al. 2004. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 24:3899-3906.
16. Weggen, S., et al. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:212-216.
17. Eriksen, J.L., et al. 2003. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112:440-449. doi:10.1172/JCI200318162.
18. Hsiao, K., et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
19. Kawarabayashi, T., et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:372-381.
20. Wang, J., Dickson, D.W., Trojanowski, J.Q., and Lee, V.M. 1999. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158:328-337.
21. Chishti, M.A., et al. 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276:21562-21570.
22. Wilcock, D.M., et al. 2004. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation. 1:24.
23. Kumar-Singh, S., et al. 2005. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am. J. Pathol. 167:527-543.
24. Racke, M.M., et al. 2005. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25:629-636.
25. Pfeifer, M., et al. 2002. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 298:1379.
26. Odaka, A., et al. 2005. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegenerative Diseases. 2:36-43.
27. Bard, F., et al. 2003. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100:2023-2028.
28. Das, P., Murphy, M.P., Younkin, L.H., Younkin, S.G., and Golde, T.E. 2001. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:721-727.
29. Das, P., and Golde, T.E. 2002. Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al. Neurobiol. Aging. 23:671-674; discussion 683-684.
30. Schenk, D. 2002. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3:824-828.
31. Lemere, C.A., et al. 2004. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165:283-297.
32. Schenk, D., et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
33. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
34. Solomon, B. 2003. Immunological approach for the treatment of Alzheimer's disease. J. Mol. Neurosci. 20:283-286.
35. Nitsch, R.M. 2004. Immunotherapy of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 18:185-189.
36. Wisniewski, T., and Frangione, B. 2005. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 15:72-77.
37. McLaurin, J., et al. 2002. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8:1263-1269.
38. Bussiere, T., et al. 2004. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 165:987-995.
39. Chauhan, N.B., Siegel, G.J., and Feinstein, D.L. 2004. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem. Res. 29:1897-1911.
40. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H., and LaFerla, F.M. 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 43:321-332.
41. Wilcock, D.M., et al. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23:3745-3751.
42. Hock, C., et al. 2003. Antibodies against beta-Amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:547-554.
43. Gilman, S., et al. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 64:1553-1562.
44. Tycko, R., and Ishii, Y. 2003. Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling. J. Am. Chem. Soc. 125:6606-6607.
45. Nicoll, J.A., et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:448-452.
46. Masliah, E., et al. 2005. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 64:129-131.
47. Bacskai, B.J., et al. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22:7873-7878.
48. Chauhan, N.B., and Siegel, G.J. 2005. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett. 375:143-147.
49. Fossati-Jimack, L., et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J. Exp. Med. 191:1293-1302.
50. Orgogozo, J.M., et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 61:46-54.